Feed

Skin cancer comprises a significant global health challenge, exacerbated by escalating ultraviolet radiation exposure, inherent genetic predispositions, and inequities in access to early diagnostic interventions. This chapter integrates contemporary insights concerning both melanoma and non-melanoma skin cancers, elucidating their epidemiological patterns, biological determinants, and the diagnostic complexities related with early or atypical manifestations. Traditional diagnostic modalities-such as clinical assessment, dermoscopy, and self-evaluation of the skin are crucial yet constrained by subjectivity, variability in practitioner expertise, and challenges in recognizing subtle lesions. These constraints have catalyzed the progression of sophisticated non-invasive technologies, including reflectance confocal microscopy, total body photography, teledermatology, electrical impedance spectroscopy, and genomic adhesive-patch testing, each of which promises improved diagnostic accuracy and the capability to mitigate unnecessary biopsies. Current treatment approaches emphasize surgery for localized disease, supplemented by radiotherapy, photodynamic therapy, and laser techniques when surgery is impractical. Targeted therapies like BRAF and MEK inhibitors provide precision for specific tumors, while combination strategies aim to overcome resistance and improve treatment durability. Swift advancements in nanotechnology, microneedle delivery systems, and topical or patch-based formulations present promising strategies for improved and enhanced dermal penetration, and minimized systemic toxicity. The chapter emphasizes the persistent evolution towards previous detection, minimally invasive diagnostic techniques, and personalized therapeutic approaches. Ongoing progressions in imaging technologies, molecular profiling, immunotherapeutic strategies, and nanomedicine are anticipated to redefine future therapeutic standards.